All In MedTech

Device Trial Radar · NCT03794011

Patch vs. No Patch Fetoscopic Meningomyelocele Repair Study

Study to Compare 2 Minimally Invasive Fetal Neural Tube Defect Repair Techniques: Repair Using Durepair Patch vs. Repair Without Durepair Patch

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

38

Actual

Start

Dec 18, 2018

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Baylor College of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 4, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the maternal, fetal and neonatal outcomes of a cohort of 60 patients in whom a multilayer closure with a Durepair patch is performed with a prior cohort of patients in whom a standardized repair without patch (n = 32) was performed using the same minimally invasive fetoscopic repair technique. The hypothesis is that there will be a thicker repair (as measured by MRI at 6 weeks post surgery) and less MMC repair dehiscence and/or CSF leak with the patch repair.

Conditions

  • Neural Tube Defects

Interventions

  • fetoscopyDevice

    The fetoscopic arm is described above. Patients who have an appropriate window (posterior placenta) and choose fetoscopic surgery will be offered the two fetoscopic options, (i) laparotomy assisted and, (ii) totally percutaneous expandable port assisted. Patients with an anterior placenta will only be offered the lapartotomy assisted approach. All patients will undergo a fetoscopic repair of the fetal open neural tube defect including a the use of a Durepair patch.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MMC Repair Dehiscence and/or CSF leakTime frame: at birth

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University: Lucille Packard's Children's Hospital

    Stanford, California

  • Texas Childrens Hospital

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.